PHATHOM PHARMACEUTICALS INC. - COMMON STOCK

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

19 8 2024 05:00:19 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

08 8 2024 05:00:08 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients

30 7 2024 05:00:01 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024

29 7 2024 04:59:41 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

18 7 2024 05:00:50 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

28 5 2024 05:00:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting

15 5 2024 05:00:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

09 5 2024 05:00:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024

29 4 2024 05:00:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

03 4 2024 05:00:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

26 3 2024 05:00:05 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

07 3 2024 05:00:50 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

29 2 2024 05:00:49 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients

13 2 2024 05:00:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

31 1 2024 05:00:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital

14 12 2023 05:00:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

06 12 2023 05:00:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

28 11 2023 05:00:28 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates

09 11 2023 05:00:01 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

01 11 2023 14:00:26 提供 Nasdaq GlobeNewswire